Peptide Health Lab

Cognitive & neuro

Pinealon

FOR RESEARCH PURPOSES ONLY

Also known as: EDR peptide, Glu-Asp-Arg

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed September 1, 2026 · 15 sources

What Pinealon is and how it works

Pinealon is a synthetic tripeptide, Glu-Asp-Arg, abbreviated EDR. It belongs to the family of "short peptide bioregulators" developed at the St Petersburg Institute of Bioregulation and Gerontology, and three things about that description matter before anything else. It is synthetic, not an extract of anything. Despite the name, it is not a pineal gland preparation. And it is not the tetrapeptide AEDG that the same programme produced — a different molecule with a different literature, whose results do not transfer here.

The proposed mechanism is epigenetic and unusually literal: the peptide is said to enter the nucleus and bind DNA directly. Fluorescently labelled short peptides including this one were observed in the cytoplasm, nucleus and nucleolus of HeLa cells, and fluorescence-quenching measurements indicated binding to deoxyribo-oligonucleotides that was sequence-preferential and sensitive even to cytosine methylation status.[8] A physical-chemistry study using spectroscopy, NMR, viscosimetry and molecular dynamics reported that the tripeptide partly penetrates the major groove of DNA and contacts the N7 and O6 atoms of guanine, with magnesium ions promoting the interaction.[9] Docking work has modelled binding sites in the promoter regions of genes whose protein products are implicated in Alzheimer's pathogenesis, and separate modelling of 26 ultrashort peptides against the LAT and PEPT transporter families named this tripeptide among the most effective ligands — a computational result about how it might reach the inside of a cell, not a measurement that it does.[5][12]

The institute's own review sets out the full proposed chain in its own words: the peptide is assumed to enter cells and bind to histone proteins and/or ribonucleic acids, and thereby to shift the MAPK/ERK pathway and the synthesis of pro-apoptotic proteins, antioxidant enzymes and transcription factors.[11] The histone step in particular is an assumption in the review that proposes it, not an observation anyone has published. None of the chain has been measured in a living person.

What the research actually shows

Oxidative and hypoxic protection, in cells and animals. The tripeptide produced dose-dependent restriction of reactive oxygen species accumulation in cerebellar granule cells, neutrophils and PC12 cells under receptor-dependent and receptor-independent oxidative stress, and reduced necrotic cell death, with a delayed time course of ERK1/2 activation and a modified cell cycle.[1] In a hypobaric hypoxia model, it produced the most pronounced antihypoxic effect among the four short peptides compared, which the investigator attributed less to direct radical scavenging than to stimulation of the animals' own antioxidant enzyme system. The Russian-language abstract names no species.[3]

A behavioural result in rats. Rats were made hyperhomocysteinemic by dietary methionine loading during pregnancy. Treating the pregnant animals improved their offspring's spatial orientation and learning ability, and left the offspring's cerebellar neurons with less reactive oxygen species accumulation and fewer necrotic cells.[2] This is the clearest in vivo result on the page, and it is a developmental insult model rather than a model of ordinary cognitive ageing.

Synapses, in dishes and in mice. In primary mouse hippocampal neuron culture under amyloid synaptotoxicity, 200 nanograms per millilitre of the tripeptide raised mushroom spine number by 71% and returned it to the untreated level; the companion tripeptide KED raised it by 20%.[4] In 5xFAD mice, both peptides prevented dendritic spine loss. The reported intraperitoneal schedule in that paper — 400 micrograms per kilogram daily from two to four months of age — is stated for KED, not for this tripeptide.[5] The paper carries a published correction: two of its figures had been duplicated and described differently, corrected figures were issued, and the authors stated that the scientific conclusions were unaffected.[6] Related cell work reported that this tripeptide and KED stimulated serotonin expression in ageing cultures of brain cortex cells, with molecular docking offered as the proposed mechanism.[10]

The most relevant human-cell model, reported in full. In 2024, dermal fibroblasts from elderly donors were transdifferentiated into induced cortical neurons — a model built specifically to represent aged human neurons. This tripeptide, along with KED and AEDG, promoted arborization of the dendritic tree, increasing both the number of primary processes and total dendrite length, and this tripeptide specifically reduced oxidative DNA damage. In the same experiment, the tripeptides had no effect on mitochondrial activity, no effect on lysosomal activity, and no effect on the senescence marker p16. The authors described the protection as partial.[7]

People. Two indexed reports gave this tripeptide to human beings, both in Russian, both non-blinded, and both administering it together with a second peptide rather than alone. One examined 150 lorry drivers against 150 metal craftsmen for occupational borderline mental disorders and reported that applying bioregulating peptides restored adaptive potential and improved psychoemotional indices, with the best effect from this tripeptide combined with Vesugen.[13] The other gave the same pair to 32 patients aged 41–83 with polymorbidity and organic brain syndrome, reported improved central nervous system activity and a slowed rate of ageing by biological-age indicators, judged the companion peptide the more effective of the two, and also reported pro-oxidant activity by chemiluminescence and a decrease in circulating CD34-positive haematopoietic progenitor cells.[14]

Where the evidence is weak

There is no controlled human trial of this compound against a cognitive endpoint. That is the whole reason most readers arrive at this page, and the answer is that the study has not been done. The two human reports have no control group in the sense a trialist would recognize, are not blinded, and gave two peptides at once, so nothing in either can be attributed to this tripeptide specifically.[13][14]

One human study reported findings that cut against the framing. The same 32-patient report describes pro-oxidant activity and inhibition of haemopoiesis alongside its favourable indices, and its authors classify the peptides as anabolic neuroprotectors "of no antioxidant type" — which is not how the compound is usually described.[14][1]

The mechanism is proposed, and the evidence for it is biophysical. DNA binding was measured in flasks and quenching assays; transporter feasibility was computed; the histone binding that the mechanism is usually described with was never measured at all, and the institute's own review states it as an assumption. No study has demonstrated that this tripeptide reaches a human neuronal nucleus after administration, because no study has measured what happens to it after administration at all.[8][9][12][11]

The most relevant ageing model found as many nulls as effects. Reporting the dendritic arborization without the absence of any effect on mitochondria, lysosomes or p16 would misdescribe that paper. Both halves are the result.[7]

Almost the entire literature comes from one institute and its collaborators. Papers about this tripeptide are overwhelmingly authored from St Petersburg, and there is no independent replication of the animal or human work by an unaffiliated group. The reviews that discuss it from outside that community characterize the short peptides as mechanistically interesting and clinically untested, and note the current lack of clinical trials.[15] Where a paper studies a family of short peptides and reports this one as a member, that is a class-level finding, and this page has tried to say so each time it uses one.[3][12]

Long-term safety is unknown. The rodent and cell studies were designed to detect protection over days to weeks. Nothing in the published record speaks to sustained exposure in a person, and a mechanism built on altering gene transcription is not a mechanism where absence of reported harm should be reassuring.[11]

Legal and regulatory status

Pinealon is not approved by the FDA for any indication. A search of approved drug products under the compound name, the EDR designation and the Glu-Asp-Arg sequence returns no application with this peptide as an active ingredient and no approved labeling, while a control query of the same shape run in the same session returned approved biologic applications as expected. It does not appear in any category of the FDA's list of bulk drug substances nominated for use in compounding under section 503A, in which other research peptides do appear. It is neither an approved drug nor a dietary supplement ingredient in the United States; material carrying the name is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing.

The compound originates in Russian gerontology research, and short peptide bioregulator preparations of this family are marketed in Russia. PHL was not able to establish a marketing authorization for this tripeptide as a registered medicine in any jurisdiction, and reports that as the limit of what it verified rather than as a finding either way. A preparation being marketed in another country is not a regulatory approval, a status granted elsewhere is not a status in the United States, and neither substitutes for a review the FDA has not conducted. Reviews published outside the originating community place the short peptide bioregulators among the compounds with preclinical support and no completed clinical programme.[15]

PHL does not sell peptides, does not tell anyone where to obtain anything, and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything carrying this name.

Questions to bring to a provider

The productive conversation is not "should I try Pinealon." It is "here is the cognitive or neurological concern I actually have, and where does a tripeptide with no controlled human trial sit relative to the things that do have evidence?" Questions worth raising:

  • What is actually being measured — memory, attention, mood, fatigue — and is there a standard assessment that would establish a baseline before anything changes?
  • Given that the human reports gave two peptides together with no control group, what would a study have to look like before it could say anything about this one?[14]
  • Does the reported decrease in circulating CD34-positive cells in that study change how a person with any haematological history should think about it?[14]
  • If the proposed mechanism is direct interaction with DNA and gene transcription, what would a clinician want to know about interactions with anything currently prescribed, or about pregnancy planning?[9]
  • What do the standard reversible contributors to cognitive complaints — thyroid, B12, sleep apnoea, medication burden, depression — look like in this case, and have they been ruled out first?
  • Which specific test or functional measure would tell either of us whether anything actually changed?[7]

A clinician who answers "there is no controlled human trial to reason from" is describing the literature accurately.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Protection of neurons against oxidative and hypoxic stress in cells and animals
Animal studies only in vitro · animal

This is the compound's strongest layer. In cerebellar granule cells, neutrophils and PC12 cells, the tripeptide restricted reactive oxygen species accumulation in a dose-dependent way and reduced necrotic cell death, with a delayed time course of ERK1/2 activation. In a model of hypobaric hypoxia it produced the most pronounced antihypoxic effect among the four short peptides tested, which the author attributed to stimulation of the endogenous antioxidant enzyme system rather than to direct radical scavenging; the Russian-language abstract of that study names no species. Cell culture and one animal hypoxia model, and nothing above that.

[1] [3]

Cognitive and behavioural outcomes in rodents
Animal studies only animal

In the offspring of rats made hyperhomocysteinemic by dietary methionine loading during pregnancy, maternal treatment improved the offspring's spatial orientation and learning ability and left their cerebellar neurons more resistant to oxidative stress, with less reactive oxygen species accumulation and fewer necrotic cells. This is the clearest in vivo result with a behavioural endpoint, and it is a developmental-insult model in rats rather than a model of ordinary cognitive ageing.

[2]

Dendritic spines and neuroplasticity in Alzheimer's models
Animal studies only in vitro · animal

In primary mouse hippocampal neurons under amyloid synaptotoxicity, 200 nanograms per millilitre of the tripeptide increased mushroom spine number by 71% and returned it to the normal level, while the companion tripeptide KED produced a 20% increase. In 5xFAD mice, both peptides prevented dendritic spine loss. The 5xFAD paper carries a published correction: two figures had been duplicated and described differently, and the corrected figures were issued with the authors stating the scientific conclusions were unaffected.

[4] [5] [6]

Protection of aged human neurons in culture
Animal studies only in vitro

In induced cortical neurons transdifferentiated from elderly donors' dermal fibroblasts, this tripeptide and two companions all promoted dendritic arborization, increasing both the number of primary processes and total dendrite length, and this tripeptide specifically reduced oxidative DNA damage. In the same experiment the tripeptides had no effect on mitochondrial activity, lysosomal activity, or p16. The authors described the protection as partial, and the result is a cell-culture one regardless of the cells' human origin.

[7]

Sequence-specific interaction with DNA as the proposed epigenetic mechanism
Animal studies only in vitro · animal · review

Fluorescently labelled short peptides including this one entered the cytoplasm, nucleus and nucleolus of HeLa cells, and fluorescence-quenching constants indicated sequence-preferential binding to deoxyribo-oligonucleotides that discriminated even cytosine methylation status. Spectral, NMR, viscosimetry and molecular-dynamics work reported that the tripeptide partly enters the major groove of DNA and contacts guanine N7 and O6, with magnesium ions promoting the interaction. Separate docking work modelled binding sites in the promoter regions of genes implicated in Alzheimer's pathogenesis, and molecular modelling with computer-assisted docking of 26 ultrashort peptides against the LAT and PEPT transporter families named this tripeptide among the most effective ligands — a calculation, with no bench experiment behind it. All of it is biophysics, cell culture and computation. It is a proposed mechanism, not a demonstrated one in an organism.

[8] [9] [5] [12]

Cognitive benefit in people
Anecdotal reports only human observational · review

No controlled trial has tested this tripeptide alone against a cognitive endpoint in humans. Two indexed Russian-language reports exist and both administered peptide combinations. One compared neurobehavioural status in 150 lorry drivers against 150 metal craftsmen and reported that applying bioregulating peptides improved psychoemotional indices, with the best effect from combining this tripeptide with Vesugen; it was an occupational cross-sectional comparison with the peptide application layered on, not a randomized trial. The other gave this tripeptide with Vesugen to 32 patients with polymorbidity and organic brain syndrome and reported improved central nervous system activity, again with no control group and with the companion peptide judged the more effective of the two. A review from the originating institute also states that the peptide improves memory in elderly patients; that is a review's assertion rather than an indexed trial this page can point at.

[13] [14] [11]

Slowing biological ageing in people
Anecdotal reports only human observational

The single indexed human study that framed itself this way reported a slowed rate of ageing by biological-age indicators in 32 uncontrolled patients receiving two peptides together, alongside pro-oxidant activity and reduced circulating CD34-positive cells. The investigators judged the companion peptide the more effective of the two. Nothing in that design supports an anti-ageing claim for this tripeptide.

[14]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • Primary culture of mouse hippocampal neurons under amyloid synaptotoxicity, the in vitro Alzheimer's model in which the tripeptide's clearest cell-level effect was measured

    200 nanograms per millilitre added to the culture medium, which increased the number of mushroom spines by 71% and returned the count to the untreated-control level [4]

  • The 5xFAD mouse Alzheimer's model, in which the reported intraperitoneal schedule belongs to the companion tripeptide KED rather than to EDR

    Daily intraperitoneal administration from 2 to 4 months of age at 400 micrograms per kilogram is the figure the authors report, and they report it for KED; no corresponding EDR schedule appears in the abstract, so no EDR animal dose can be stated from this study [5]

  • Humans, administered the EDR tripeptide alone, any indication

    No dose is established. The two indexed human reports gave this tripeptide together with a second short peptide rather than alone, and neither describes an EDR amount or schedule in its abstract [13] [14]

Every usable figure above comes from a dish or a mouse, and the one animal schedule in the literature is reported for a different tripeptide in the same experiment. Community-circulated human schedules have no published source behind them and therefore do not appear here.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No characterized human safety profile

    Not established · Unknown, and that is an absence of data rather than a finding of safety. No published trial has administered this tripeptide alone to people under a described protocol, so there is no adverse-event table, no dose-limiting toxicity, and no human pharmacokinetic description to reason from. A review published outside the originating research community describes the short peptide bioregulators as preclinically promising and notes the current lack of clinical trials.

    [15]

  • Pro-oxidant activity and reduced circulating haematopoietic progenitors

    Reported in a 32-patient uncontrolled study of two peptides given together · In the only indexed human study that measured laboratory endpoints, 32 patients aged 41–83 received this tripeptide together with Vesugen. The investigators reported an anabolic effect and improved central nervous system indices, but also pro-oxidant activity by chemiluminescence and a decrease in circulating CD34-positive haematopoietic progenitor cells, which they read as significant inhibition of haemopoiesis. They did report that neither peptide affected chromatin condensation. The study had no control group and both peptides were given together, so nothing here can be attributed to EDR specifically — but a reported signal in the marrow compartment is a provider-discussion flag rather than a footnote.

    [14]

  • Direct interaction with DNA as the proposed mechanism

    Described as the primary proposed mechanism · The mechanism this compound is built on is direct, sequence-preferential interaction with DNA, reported from fluorescence-quenching work in HeLa cells and from spectral, NMR and molecular-dynamics measurements of major-groove contact. Binding to histone proteins is assumed rather than shown: the institute's own review states that the peptide is assumed to enter cells and bind to histone proteins and/or ribonucleic acids. A molecule proposed to alter which genes are transcribed is not obviously a low-consequence intervention, and no published work has examined what repeated exposure does in a person, including in pregnancy or alongside any prescribed medication. The absence of a reported harm is not a finding of no harm.

    [8] [9] [11]

  • Effects that were looked for and not found

    Reported in induced neurons from elderly donors · In induced cortical neurons transdifferentiated from the dermal fibroblasts of elderly donors, the tripeptides had no effect on mitochondrial activity, no effect on lysosomal activity, and no effect on the senescence marker p16. That is not a harm signal, but it does bound what the compound was shown to do in the most directly relevant human-cell ageing model published to date, and it is the half of that paper least likely to be quoted.

    [7]

  • Unverified identity and purity of unapproved material

    Not quantified · With no approved manufacturer, nothing about the sequence fidelity, concentration, or contaminant profile of material carrying this name is regulated or independently guaranteed. The risk is heightened for a three-residue peptide whose closest relatives in the same research programme differ by one or two amino acids and are discussed under similar names. This is a category-level risk on top of whatever the molecule itself does.

    [11]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Lyophilized short peptides are conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for longer holding. No published stability study exists for this tripeptide; the literature is concerned with what the molecule does in cells and animals rather than with how long a vial keeps, so the conventions here come from general lyophilized-peptide practice rather than from data about this compound.
Reconstituted storage
Once in solution, short peptides are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. No published study establishes a solution shelf life for this tripeptide.
Reconstitution diluent
Bacteriostatic water — sterile water preserved with 0.9% benzyl alcohol — is the conventional diluent for lyophilized research peptides, including short peptides of this family. Preservative-free sterile water is used where a preservative is contraindicated and is treated as single-use.
Reconstitution & handling
Conventional handling only: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let the powder dissolve on its own. Swirl gently if needed; never shake. A properly prepared solution is clear, and anything cloudy, discolored, or carrying visible particulate is discarded. PHL publishes no volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
There is no FDA-approved manufacturer, so there is no label, no assigned beyond-use date, and no lot-level stability testing behind any storage claim. Everything above is convention, not specification. Preparations carrying this name in other countries are formulated differently from a research powder and their handling is a separate question this page does not address.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

15 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder